Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), speaks with Chris Houchin, Partner at Guidehouse, in a video interview about the challenges and opportunities of using data sets for rare disease treatment, using decentralized trials, and the possibility of leveraging real-world evidence for cell and gene therapies, and partnering with the FDA.